secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001104659-25-060092
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker partners Cellipont for cGMP manufacturing of MT-601 for lymphoma trial
-----------------------------------------------------------------------------

- Partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, a MAR-T cell therapy for lymphoma in Phase 1 APOLLO study.
- APOLLO study previously reported 78% objective response (7/9) and 44% complete response (4/9) at 4 weeks post MT-601 infusion.
- Cellipont to provide technology transfer and cGMP manufacturing services over approximately nine months to support clinical supply.
- Collaboration designed to enable potential pivotal trial and commercial readiness; Cellipont facility in The Woodlands, TX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925060092/0001104659-25-060092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925060092/tm2518163d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-060092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer